Continuous Glucose Monitoring– tag –
-
FDA Approves Firmware Update for Dexcom G5 Mobile Continuous Glucose Monitoring System
FDA.gov USA Overview The U.S. FDA has approved minor design changes to the firmware installed on the transmitter component of the Dexcom G5 Mobile Continuous Glucose Monitoring System. Issued as a Premarket Approval (PMA) supplement, thi... -
Dexcom Secures FDA Authorization for Stelo Glucose Biosensor System, First OTC CGM for Non-Diabetic and Non-Insulin Using Individuals
Devices@FDA (Dexcom) USA Overview Dexcom, Inc. has received FDA authorization for its 'Stelo Glucose Biosensor System,' marking it as the first over-the-counter (OTC) integrated continuous glucose monitor (iCGM) specifically for individu... -
HealthPartners Launches Program Expanding CGM Access and Integrating Pharmacist Support for Insulin-Treated Diabetics
Morningstar (HealthPartners) USA Overview HealthPartners has initiated a new quality improvement program aimed at expanding access to continuous glucose monitoring (CGM) technology and providing personalized support for diabetic patients... -
Boston University Identifies Cardiovascular Metabolic Risk Patterns in Non-Diabetic Adults via CGM Data
EurekAlert! (Boston University Chobanian & Avedisian School of Medicine) USA Overview Researchers at Boston University have discovered that glucose patterns recorded by continuous glucose monitoring (CGM) devices in non-diabetic adults a... -
Abbott Receives FDA Authorization for Libre Duo 10 Day: World’s First Dual Continuous Glucose and Ketone Monitoring System for Early DKA Warning
Medical Update Online (Abbott) USA Overview Abbott has secured FDA authorization for its Libre Duo 10 Day, the world's first dual continuous glucose and ketone monitoring (CGKM) system. This novel bio-wearable provides real-time glucose ... -
Future of Continuous Glucose Monitoring: IDF Europe Advocates User-Centric Approach for Technology Selection in 2026
IDF Europe Belgium Overview IDF Europe has released an expert opinion asserting that Continuous Glucose Monitoring (CGM) has become an indispensable tool transforming diabetes management and supporting personalized care by 2026. Newer ge... -
FDA Classifies Continuous Glucose Monitor Retrospective Data Analysis Software as Class I, 510(k) Exempt Medical Device
FDA.gov USA Overview The U.S. FDA has classified continuous glucose monitor retrospective data analysis software (Product Code PHV) as a Class I medical device, exempting it from 510(k) premarket notification. This software is intended t... -
FDA Approves Minor Firmware Design Changes for Dexcom G5 Mobile CGM System Transmitter Component
FDA.gov USA Overview The U.S. FDA has granted a Premarket Approval (PMA) supplement for minor design changes to the firmware installed on the transmitter component of the Dexcom G5 Mobile Continuous Glucose Monitoring System. This approv... -
Five Key Trends in Diabetes Technology for 2026: Longer-Lasting CGMs, OTC Expansion, and Multi-Biomarker Monitoring Lead Innovation
DiabeticSupplieInc.com Unknown Overview Five major trends are shaping diabetes technology in 2026, including longer-lasting continuous glucose monitoring (CGM) sensors like the FDA-cleared Dexcom G7 15-day system, expanded CGM access for... -
FDA Approves Dexcom’s Stelo System as First Over-the-Counter Continuous Glucose Monitor for Children Ages 2-18
RadioWHAT (Facebook) USA Overview The FDA has approved Dexcom's Stelo system as the first over-the-counter (OTC) continuous glucose monitor (CGM) available for children aged 2 to 18 without a prescription. This device provides 15-minute ...
